Unnati Pharmax

Formost Inhaler
Composition: Formoterol Fumarate + Mometasone Furoate Inhalation Aerosol
International Trade Name: Formost®

Formost Inhaler is a high-quality combination inhaler containing Formoterol, a long-acting beta-2 adrenergic agonist (LABA), and Mometasone Furoate, an inhaled corticosteroid (ICS), formulated for the management of asthma and chronic obstructive pulmonary disease (COPD). Manufactured in WHO-GMP certified facilities, Formost Inhaler is supplied by trusted pharmaceutical exporters from India to support global respiratory care programs.

Formoterol provides prolonged bronchodilation by relaxing bronchial smooth muscles, helping prevent bronchospasm and improve airflow. Mometasone Furoate suppresses airway inflammation, reduces swelling, and minimizes mucus production, enhancing long-term control of respiratory symptoms. The combination provides both immediate symptom relief and preventive control of chronic respiratory conditions.

Formost Inhaler is primarily indicated for the maintenance treatment of asthma in adults and children, and for the management of stable COPD where inhaled corticosteroids and long-acting bronchodilators are indicated. It is suitable for patients under medical supervision as part of a comprehensive respiratory management plan.

Formost Inhaler (Formoterol + Mometasone) is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The inhaler is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, respiratory clinics, retail pharmacies, and international pharmaceutical distributors.

Formonide 400 Inhaler
Composition: Formoterol Fumarate & Budesonide Inhalation Aerosol
International Trade Name: Formonide®

Formonide 400 is a high-quality combination inhaler containing Formoterol Fumarate, a long-acting beta-2 adrenergic agonist (LABA), and Budesonide, an inhaled corticosteroid (ICS), formulated for the management of asthma and chronic obstructive pulmonary disease (COPD). Manufactured in WHO-GMP certified facilities, Formonide 400 Inhaler is supplied by trusted pharmaceutical exporters from India to support global respiratory care programs.

Formoterol provides prolonged bronchodilation by relaxing bronchial smooth muscles, helping prevent bronchospasm and improve airflow, while Budesonide reduces airway inflammation, swelling, and mucus production, enhancing long-term control of respiratory symptoms. The combination provides both immediate symptom relief and preventive management of chronic respiratory conditions.

Formonide 400 Inhaler is primarily indicated for the maintenance treatment of asthma in adults and children, and for the management of stable COPD where inhaled corticosteroids and long-acting bronchodilators are required. It is suitable for patients under medical supervision as part of a comprehensive respiratory therapy plan.

Formonide 400 (Formoterol Fumarate & Budesonide) Inhaler is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The inhaler is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, respiratory clinics, retail pharmacies, and international pharmaceutical distributors.

Seroflow 250 Inhaler
Composition: Budesonide & Formoterol Fumarate Inhalation
International Trade Name: Seroflow®

Seroflow 250 is a high-quality combination inhaler containing Budesonide, a corticosteroid, and Formoterol Fumarate, a long-acting beta-2 agonist (LABA), indicated for the management of asthma and chronic obstructive pulmonary disease (COPD). Manufactured in WHO-GMP certified facilities, Seroflow 250 Inhaler is supplied by trusted pharmaceutical exporters from India to support global respiratory care programs.

Budesonide works by reducing airway inflammation, edema, and hyper-responsiveness, while Formoterol relaxes the smooth muscles of the bronchi, providing long-lasting bronchodilation. The synergistic action of these agents helps improve airflow, reduce exacerbations, and enhance overall lung function in patients with asthma and COPD.

Seroflow 250 Inhaler is primarily indicated for maintenance therapy in asthma, prevention of bronchospasm, and long-term management of COPD. It is suitable for adult and adolescent patients under medical supervision and should be used regularly for optimal disease control.

Seroflow 250 Budesonide & Formoterol Inhaler is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The inhaler is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, respiratory clinics, retail pharmacies, and international pharmaceutical distributors.

Formonide 200 Inhalation
Composition: Formoterol Fumarate & Budesonide Inhalation
International Trade Name: Formonide®

Formonide 200 is a high-quality combination inhalation therapy containing Formoterol Fumarate, a long-acting beta-2 adrenergic agonist (LABA), and Budesonide, a corticosteroid, indicated for the management of asthma and chronic obstructive pulmonary disease (COPD). Manufactured in WHO-GMP certified facilities, Formonide 200 Inhalation is supplied by trusted pharmaceutical exporters from India to support global respiratory care programs.

Formoterol works by relaxing the smooth muscles of the bronchi, providing rapid and long-lasting bronchodilation, while Budesonide reduces airway inflammation, swelling, and hyper-responsiveness. Together, they improve airflow, reduce symptoms, and help prevent exacerbations, offering effective long-term management of obstructive airway diseases.

Formonide 200 Inhalation is primarily indicated for maintenance therapy in asthma, prevention of bronchospasm, and long-term management of COPD. It is suitable for adult and adolescent patients under medical supervision and should be used regularly for optimal disease control.

Formonide 200 Formoterol Fumarate & Budesonide Inhalation is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The inhaler is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, respiratory clinics, retail pharmacies, and international pharmaceutical distributors.

Combimist L Respules
Composition: Salbutamol 2.5mg + Ipratropium Bromide 0.5mg per 2ml Inhalation Solution
International Trade Name: Combimist L®

Combimist L Respules is a high-quality inhalation solution combining Salbutamol, a short-acting beta-2 adrenergic agonist, and Ipratropium Bromide, a short-acting anticholinergic bronchodilator, for the effective management of obstructive airway diseases. Manufactured in WHO-GMP certified facilities, Combimist L Respules are supplied by trusted pharmaceutical exporters from India to support global respiratory care programs.

Salbutamol works by relaxing bronchial smooth muscles, providing rapid relief from bronchospasm and wheezing, while Ipratropium Bromide inhibits parasympathetic-mediated bronchoconstriction, enhancing bronchodilation and improving airflow. The combination provides synergistic relief from acute and chronic respiratory symptoms.

Combimist L Respules are primarily indicated for the treatment and management of chronic obstructive pulmonary disease (COPD), asthma, and other obstructive airway disorders. They are suitable for adult and pediatric patients under medical supervision, particularly when nebulized therapy is required for rapid symptom relief.

Combimist L Respules (Salbutamol + Ipratropium Bromide) are manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The solution is supplied in sterile, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, respiratory clinics, retail pharmacies, and international pharmaceutical distributors.

Omalirel Injection
Composition: Omalizumab 150mg for Injection
International Trade Name: Xolair®

Omalirel is a high-quality Omalizumab 150mg injection, a recombinant humanized monoclonal antibody designed for the targeted management of severe allergic conditions, including asthma. Manufactured in WHO-GMP certified facilities, Omalirel Injection is supplied by trusted pharmaceutical exporters from India to support global respiratory and immunology treatment programs.

Omalizumab works by selectively binding to immunoglobulin E (IgE), inhibiting its interaction with high-affinity receptors on mast cells and basophils. This mechanism reduces the release of inflammatory mediators responsible for allergic reactions, thereby controlling symptoms such as wheezing, shortness of breath, and other IgE-mediated hypersensitivity responses.

Omalirel Injection is primarily indicated for the treatment of moderate to severe persistent allergic asthma in patients whose symptoms are inadequately controlled with inhaled corticosteroids. It is also indicated for chronic spontaneous urticaria in patients who remain symptomatic despite H1 antihistamine therapy. The injection is suitable for adult and pediatric patients under strict medical supervision in hospital or clinical settings.

Omalirel Omalizumab 150mg Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, tamper-proof, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, allergy and asthma clinics, tertiary care centers, and international pharmaceutical distributors.

Arzep Nasal Spray
Composition: Azelastine Hydrochloride Nasal Spray
International Trade Name: Arzep®

Arzep is a high-quality Azelastine Hydrochloride nasal spray, a potent second-generation antihistamine indicated for the relief of allergic rhinitis and related nasal symptoms. Manufactured in WHO-GMP certified facilities, Arzep Nasal Spray is supplied by trusted pharmaceutical exporters from India to support global ENT and allergy care programs.

Azelastine Hydrochloride works by selectively blocking histamine H1 receptors in the nasal mucosa, reducing sneezing, nasal congestion, itching, and runny nose associated with seasonal and perennial allergic rhinitis. Its rapid onset of action provides quick symptomatic relief while maintaining a favorable safety profile.

Arzep Nasal Spray is primarily indicated for the management of allergic rhinitis, including seasonal and perennial forms, as well as relief of nasal symptoms associated with other allergic conditions. It is suitable for adult and pediatric patients under medical supervision.

Arzep Azelastine Hydrochloride Nasal Spray is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The spray is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, ENT clinics, retail pharmacies, and international pharmaceutical distributors.

Budepress Inhaler
Composition: Formoterol Fumarate & Budesonide Inhalation
International Trade Name: Symbicort®

Budepress is a high-quality combination inhaler containing Formoterol, a long-acting β2-adrenergic agonist (LABA), and Budesonide, an inhaled corticosteroid (ICS), designed for the management of asthma and chronic obstructive pulmonary disease (COPD). Manufactured in WHO-GMP certified facilities, Budepress Inhaler is supplied by trusted pharmaceutical exporters from India to support global respiratory care and pulmonary treatment programs.

Formoterol works by relaxing bronchial smooth muscles, providing rapid and sustained bronchodilation, while Budesonide reduces airway inflammation, swelling, and hyperresponsiveness. The combination of these agents ensures effective symptom control, improves lung function, and reduces the risk of exacerbations in patients with asthma and COPD.

Budepress Inhaler is primarily indicated for the treatment of moderate-to-severe asthma and for maintenance therapy in COPD patients with a history of exacerbations. It is suitable for adult and pediatric patients as prescribed by healthcare professionals, providing both relief from bronchospasm and long-term airway inflammation management.

Budepress Formoterol & Budesonide Inhalation is manufactured under stringent GMP and pharmaceutical quality standards, ensuring consistent efficacy, safety, and long-term stability. The inhaler is supplied in secure, tamper-proof, export-grade packaging with complete regulatory documentation, making it suitable for hospitals, pulmonary clinics, respiratory care centers, retail pharmacies, and international pharmaceutical distributors.